Avastin (bevacizumab) • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Krazati (adagrasib) • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)

DAREON-8: DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer (clinicaltrials.gov)

P1, N=46, Active, not recruiting, Boehringer Ingelheim | Trial primary completion date: Dec 2025 --> Sep 2026

1 day ago

Trial primary completion date

cisplatin • Tecentriq (atezolizumab) • carboplatin • Imfinzi (durvalumab) • etoposide IV • obrixtamig (BI 764532)

IMMUNOGLYPIC: Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy (clinicaltrials.gov)

P=N/A, N=240, Recruiting, Assistance Publique - Hôpitaux de Paris | N=120 --> 240

2 days ago

Enrollment change • IO biomarker

Tecentriq (atezolizumab) • Imfinzi (durvalumab)

BRIDGE: Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC (clinicaltrials.gov)

P2, N=10, Terminated, Mario Negri Institute for Pharmacological Research | Trial completion date: Jun 2026 --> Jan 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2026 --> Jan 2025; Low enrolment rate

2 days ago

Trial completion date • Trial termination • Trial primary completion date

PD-L1 (Programmed death ligand 1)

cisplatin • carboplatin • Imfinzi (durvalumab) • pemetrexed • vinorelbine tartrate

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer (clinicaltrials.gov)

P1/2, N=208, Recruiting, IDEAYA Biosciences | N=90 --> 208

3 days ago

Enrollment change

Imfinzi (durvalumab) • IDE161

Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas (clinicaltrials.gov)

P2, N=41, Not yet recruiting, University of Alabama at Birmingham | Trial completion date: Dec 2031 --> May 2032 | Trial primary completion date: Dec 2030 --> May 2031

3 days ago

Trial completion date • Trial primary completion date

Imfinzi (durvalumab) • Koselugo (selumetinib)

NCI-2018-01581: Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer (clinicaltrials.gov)

P2, N=70, Recruiting, National Cancer Institute (NCI) | Trial completion date: Nov 2025 --> Dec 2026 | Trial primary completion date: Nov 2025 --> Dec 2026

3 days ago

Trial completion date • Trial primary completion date

HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD4 (CD4 Molecule)

HER-2 negative • PD-L1 negative

carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • Imjudo (tremelimumab-actl) • Trodelvy (sacituzumab govitecan-hziy) • Hiltonol (poly-ICLC)

Precision Targeted-Immunotherapy for BRAF V600E and MET-Amplified Biliary Tract Cancer: Two Case Reports. (PubMed, Oncologist)

Combining targeted therapies with immune checkpoint inhibitors showed promising results in two patients with advanced BTC driven by specific genetic mutations. Significant tumor reduction and successful surgeries suggest this approach may improve resectability and outcomes. These cases highlight the potential of personalized treatment guided by genetic profiling. Further research is needed to confirm these findings and explore broader applications for this strategy.

3 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

BRAF (B-raf proto-oncogene) • MET (MET proto-oncogene, receptor tyrosine kinase)

BRAF V600E • BRAF V600 • MET amplification

Mekinist (trametinib) • Tafinlar (dabrafenib) • Imfinzi (durvalumab) • Tepmetko (tepotinib)

Impact of KRAS G12C mutation on the efficacy of chemoradiotherapy in patients with unresectable stage II or III non-small cell lung cancer. (PubMed, Front Oncol)

There was no difference between KRASm G12C and KRASwt patients in terms of ORR (48% vs. 49%; p = 0.961) and DCR (86% vs. 84%; p = 0.903), nor when comparing KRASm to KRASwt in terms of OS (p = 0.64), PFS (p = 0.28), TTLR (p = 0.26), and TTDR (p = 0.3), with no impact after adjustment for durvalumab. KRAS G12C mutation compared to KRAS wild-type did not affect response to chemoradiotherapy, and KRAS mutations compared to KRAS wild-type were not associated with worse survival in unresectable stage II or III NSCLC treated with chemoradiotherapy.

3 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

KRAS (KRAS proto-oncogene GTPase)

KRAS mutation • KRAS G12C • KRAS wild-type • RAS wild-type • KRAS G12

Imfinzi (durvalumab)

PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy. (PubMed, J Hematol Oncol)

PACIFIC-5 met its primary endpoint of improved PFS after either cCRT or sCRT. Follow-up for overall survival is ongoing.

7 days ago

P3 data • Journal • PD(L)-1 Biomarker • IO biomarker

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)

PD-L1 expression • EGFR expression

Imfinzi (durvalumab)

COLUMBIA 1: COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC (clinicaltrials.gov)

P1/2, N=61, Active, not recruiting, MedImmune LLC | Trial completion date: Nov 2025 --> Nov 2026

7 days ago

Trial completion date

Avastin (bevacizumab) • Imfinzi (durvalumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • oleclumab (MEDI9447)